Diabetes is a condition that affects a large percentage of the population and it is the leading cause of a wide range of costly complications. Diabetes is linked to a multi-fold increase in mortality and when compared to non-diabetics, the intensity and prevalence of COVID-19 ailment among diabetic individuals are more. Since its discovery in Wuhan, COVID-19 has grown rapidly and shown a wide range of severity. Temperature, lymphopenia, non-productive cough, dyspnoea, and tiredness are recognized as the characteristic of individuals infected with COVID-19 disease. In COVID-19 patients, diabetes and other related comorbidities are substantial predictors of disease and mortality. According to a recent study, SARS-CoV-2 (the virus responsible for covid-19 disease) may also lead to direct pancreatic harm, which could aggravate hyperglycemia and potentially cause the establishment of diabetes in formerly non-diabetic individuals. This bidirectional association of COVID-19 and diabetes load the burden on health care professionals throughout the world. It is recommended that gliptin medications be taken moderately, blood glucose levels must be kept under control, ACE inhibitors should be used in moderation, decrease the number of avoidable hospitalizations, nutritional considerations, and some other prevention measures, such as immunization, are highly recommended. SARS-CoV-2 may cause pleiotropic changes in glucose homeostasis, which could exacerbate the pathophysiology of pre-existing diabetes or result in new disease processes. Graphical Abstract ga1
【저자키워드】 COVID-19, SARS-CoV-2, Diabetes Mellitus, ACE2, angiotensin-converting enzyme 2, MERS, Middle East respiratory syndrome, CDC, Centers for Disease Control and Prevention, PLpro, papain-like protease, 3CLpro, 3C-like protease, RT-PCR, Reverse transcription polymerase chain reaction, SARS-CoV-2, Severe Acute Respiratory Syndrome Corona Virus-2, S, spike protein, N, nucleocapsid protein, IL-6, Interleukin-6, E, Envelope protein, T2D, type 2 diabetes, COVID-19, Corona virus disease-19, nsp3, non-structural protein 3, M, protein membrane, HE, hemagglutinin-esterase, Glucose homeostasis, Angiotensin-converting enzyme inhibitors,